

Improving recruitment and retention of people with Parkinson's disease to clinical studies: A scoping review

Rebecca Petty¹ , Veena Agarwal^{2,3}, Jennifer Allison⁴, Sandra Bartolomeu-Pires^{2,5} , Michèle Bartlett⁶, Timothy Boey⁷ , Rebecca Croucher⁸, Helen Collins⁹, Sally Collins¹, Emma Davies¹⁰, Joy Duffen¹¹, Romy Ellis-Doyle¹², Cristina Gonzalez-Robles¹² , Jemma Inches¹³, Georgia Mills¹², Sheila Wonnacott⁶, Thomas Foltynie¹², Victoria Allgar¹ , Tom Thompson¹, Camille B. Carroll^{1,14} , Stephen Mullin¹, Marie Louise-Zeissler¹  and on behalf of the EJS ACT-PD Consortium

Abstract

Background: Timely recruitment and effective retention of participants are challenging for clinical Parkinson's disease (PD) research studies. Not achieving this can affect delivery costs and bias results.

Objective: To identify successful recruitment and retention methodologies for clinical research studies in PD.

Methods: We conducted a systematic scoping review using a Population, Intervention, Comparator, Outcome and Study design (PICOS) framework to search and screen literature within five databases for published quantitative and mixed methods studies evaluating recruitment and retention strategies of interventional and observational trials in PD.

Results: Searches identified 4608 records, of which six papers covering eight studies were included in the review following screening for eligibility. No papers on retention strategies were found that met eligibility criteria. Effective strategies for rapid recruitment included research registries and trial finders ($n = 3$), digital marketing campaigns ($n = 3$), site recruitment support ($n = 1$) and multiple referral sources ($n = 1$). Recruitment diversity was increased by online campaigns, mandatory 10% minority targets set by funders and supplemental site funding.

Conclusions: This scoping review has identified methods that can be used to increase the rate and diversity of recruitment to PD clinical studies. Retention methodologies are under-researched.

Plain language summary: Recruiting patients to clinical studies and ensuring participants complete them (known as "retention") is challenging in Parkinson's disease (PD). If studies take longer this increases costs, and if the right people do not take part in studies this can mean that results may not be representative of the PD community. Our objective is to find out what effective strategies there are to support recruitment and retention to clinical research studies in PD.

¹University of Plymouth, Plymouth, UK

²University of Southampton, Southampton, UK

³National Institute for Health Research, Southampton, UK

⁴Lead Matron R&D, University Hospital Southampton NHS Trust, Southampton, UK

⁵NIHR Applied Research Collaborations Wessex, Southampton, UK

⁶UK Expert by Experience, UK

⁷University of Liverpool, Liverpool, UK

⁸National Institute for Health Research, Clinical Research Network Wessex, UK

⁹National Institute for Health Research, Clinical Research Network Thames Valley and South Midlands, UK

¹⁰UK Parkinson's Clinical Studies Group, Sheffield, UK

¹¹Cure Parkinson's, London, UK

¹²University College London, London, UK

¹³University Hospitals Plymouth NHS Trust, UK

¹⁴Newcastle University, Newcastle, UK

Corresponding author:

Rebecca Petty, N10, ITTC 1, Plymouth Science Park, Plymouth, PL6 8BX, UK.

Email: rebecca.petty@plymouth.ac.uk



We reviewed literature within five study databases. We used the population, intervention, comparator, outcome and studies (PICOS) framework to create a search strategy based on our research question, and inclusion criteria for study selection. Important criteria were: (1) studies had to test a recruitment or retention strategy in a PD clinical research study, (2) studies had to provide evidence on how well the strategy worked. We found 4608 unique research papers, six of which described and evaluated recruitment strategies. No papers on retention strategies were found that met eligibility criteria. Successful recruitment strategies included digital marketing ($n = 3$), research registries ($n = 3$), supporting study sites ($n = 1$) and multiple sources to refer people with Parkinson's (PwP) to studies ($n = 1$). Recruitment of PwP from diverse backgrounds was enhanced by (1) online campaigns, (2) funders requesting that 10% of study participants come from diverse backgrounds 3) additional funding for research teams.

This scoping review identified methods that can be used to increase the rate and diversity of recruitment to PD clinical studies. Retention methodologies are under-researched.

Keywords

Parkinson's disease, patient recruitment, clinical trial, observational study

Received: 28 May 2024; accepted: 22 September 2024

Introduction

Parkinson's disease (PD) is a debilitating, slowly progressive neurodegenerative disease, and no therapies have been shown to halt or slow progression. PD prevalence in the United Kingdom (UK) is expected to increase to 168,000 by 2025.¹ Clinical trials are therefore required to improve health outcomes for people with PD (PwP).

Less than half of all clinical trials meet their recruitment targets, despite extensions to the recruitment window.² The reasons for this are multifaceted, including lack of research awareness, mobility and travel issues (particularly for elderly participants), as well as a mistrust in clinicians and fear of harm.³ Furthermore, once recruitment has taken place, studies can struggle to retain participants, with around a quarter of trials experiencing attrition rates of more than 10%.⁴ Problems with recruitment and retention not only affect the timely delivery of trials, but risk introducing selection bias leading to a study being underpowered, underrepresentative of the target population and with reduced accuracy and applicability of results.⁵ Disease-modification trials in PD are particularly challenging,⁶ as assessments in the OFF medication state and longer follow-up periods are often necessary.⁷ Representative recruitment to PD trials is difficult with a reported mismatch of trial participants and the intended user group of certain PD therapies, where trial populations are on average younger and with less comorbidities compared to the real-world treatment population.⁸

The aim of this scoping review is to understand strategies and methodologies that effectively improve recruitment and retention to clinical research studies in PD.

Methods

Study protocol

This scoping review protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guide for

scoping reviews⁹ and is registered on the Open Science Framework (<https://osf.io/er2jz/>).

Search strategy development

Following the protocol, a search strategy was developed based on the research question "What strategies/methodologies effectively improve recruitment and retention to clinical research studies in PD?" and mapped to the Population, Intervention, Comparator, Outcomes and Study design (PICOS) framework¹⁰ (Supplemental Material 1).

There are no existing MeSH terms for 'recruitment' or 'retention', due to their broad meaning. To inform the development of a comprehensive search strategy that would allow the capture of relevant literature, a preliminary search was carried out to identify papers that meet eligibility criteria. Four papers were identified from preliminary searches. NVIVO software (Version 14; released 14 March 2023) word cloud generator was used to find common terms based on abstracts, titles and keywords. In collaboration with a University of Plymouth Information Specialist a final search strategy was developed and reviewed in accordance with peer review of electronic search strategies (PRESS) guidelines.¹¹ The final search strategy is shown in Supplemental Material 2.

Five databases were searched to find peer reviewed articles for consideration for inclusion: MEDLINE, CINAHL, Embase and Web of Science, as well the Study Within a Trial (SWAT) database. Additional articles were identified through the screening of citations and references of any articles that met eligibility criteria throughout the study selection process.

Study selection

Quantitative and mixed method studies in English, indexed from 01/01/2008 to 05/10/2023 were included in the review. This date was selected due to the timing of considerable changes in the use of digital interventions for research

recruitment. Only randomized and non-randomized Clinical Trials of an Investigational Medicinal Product (CTIMPs) or observational studies were included in our review, and we excluded surgical and cell and gene therapy trials due to their differing nature in terms of invasiveness and motivation for participation. Search results were first screened for any duplicate entries. The title and abstract from the remaining search results were screened according to the PICOS framework. RP screened all records and a second independent review was provided by either MLZ, TB or MB who were masked to each other's decisions. The full text was also reviewed in cases where inclusion was not clear from the title and abstract. Reasons for exclusion were recorded along with screening decisions. Where there was disagreement on decisions, the full article was reviewed by both reviewers followed by a discussion to reach consensus. Where consensus could not be reached, a decision was made via consultation with a third expert reviewer (CBC).

Data extraction and synthesis

One reviewer (RP) extracted the data from the full articles (Supplemental Material 3). A second reviewer verified the extracted data (MLZ) and any differences which remained outstanding were resolved by a third expert reviewer (CBC).

Parent study characteristics

For all papers information was extracted regarding the overall aim. Study design, patient characteristics and recruitment target was then extracted for each parent study featured in a single paper.

Recruitment and retention strategies

Description of strategies used within each parent study were extracted, including modality of delivery and duration.

Comparator and outcome measures

Details of any comparators used to measure the effectiveness of strategies and their key findings were extracted, as well as a description and key findings of all other outcomes measured.

All extracted data was then narratively synthesized and presented as overall suggestions for future clinical research studies.

Results

Database search results

We identified 4608 studies through database searches. After duplicates were removed, 1659 studies remained, of which 629 were excluded by title and abstract screening. The

remaining 30 studies were assessed for eligibility via full-text screening, six of which met inclusion criteria (Figure 1).

Characteristics of included papers

All six papers included for review evaluated recruitment strategies; none evaluated retention methods. Five of the six papers were purely quantitative, and two included qualitative data.^{12,13} Three papers evaluated recruitment to CTIMPs^{12–14} and three papers to observational studies.^{15–17}

Four papers evaluated different recruitment activities within a single parent study^{12,13,15,17} and two compared recruitment activities of different parent studies.^{14,16} Three papers' main focus was on the recruitment of racial and ethnic minorities^{13–15} (Table 1).

Details of recruitment strategies and their results can be found in Table 2 and are summarized below and in Table 3.

Recruitment strategies and their effectiveness

We classified the recruitment methodologies reported in the included papers into 5 groups: (1) digital marketing campaigns which included outreach via social media, webinars, podcasts, study-specific and other website; (2) recruitment from an existing registry of participants who had previously consented to contact for future research opportunities or from trial finder platforms; (3) strategies specifically targeting minority participants; (4) physical recruitment materials including posters/flyers; (5) all other recruitment strategies. We will discuss the effectiveness of each. The strategies used varied considerably and in most papers ($n=5$) several strategies were grouped together to form an overall recruitment package (Table 2).

Digital marketing campaigns

Three of the eight studies used a digital marketing strategy which included the use of social media, podcasts, press releases and television appearances,^{12,15,17} all of which met or exceeded their recruitment target, mainly attributed to the use of social media. Other online strategies included use of a study website, either to give PwP or study staff information about the study.^{13,16}

Research registries and trial finders

Three out of four studies that used a trial finder¹² or registry database^{15,16} as part of their recruitment package met or exceeded their recruitment target. One study¹⁷ found that a North American cohort who utilized both a trial finder and research registry as part of their recruitment package recruited more effectively than a participant cohort based in the Netherlands who did not use these strategies. However, because all parent studies evaluated the use of a registry or trial finder as part of a whole recruitment package, the individual effectiveness is not clear.




Figure 1. PRISMA diagram for included studies.

Minority recruitment

The aim of three of the papers, which covered four parent studies, was to recruit a representative sample of minority participants.^{13–15} Of these, two parent studies recruited successfully. Berk et al.¹² recruited a representative sample of 10.1% racial and ethnic minorities. Recruitment strategies employed in this study included translated study and recruitment materials, local initiatives in collaboration with minority PD organizations such as the Muhammed Ali Foundation, a mandatory 10% minority inclusion target set by the study funder and a minority recruitment funding source which study sites could apply for to gain additional recruitment funding. Dobkin et al.¹⁵ used targeted social media advertising to improve recruitment of rural participants. This strategy resulted in the recruitment of 65 (18%) rural participants, compared to four (3%) in the control group who did not utilize any digital marketing strategies. The study also found that their Google advertising campaign recruited 10.7% non-white and Hispanic participants; however, as participants comprised both healthy controls and PwP, it is not known how many participants in these groups had PD.

Further insight into minority recruitment was achieved during qualitative interviews with site staff in one other paper.¹³ Here it was found that minority participants were less likely to want to be involved in the trial due to its length and economic barriers including the cost of transportation. Low enrolling sites in particular commented on the time and effort it takes to mitigate these barriers.

Physical recruitment materials

Physical study materials such as cards, brochures and thank you cards were utilized by four of the studies,^{12–14,16} but in these cases they were evaluated as part of a whole recruitment package and so their individual effectiveness is unknown. However, one study¹³ used qualitative interviews to discuss how low enrolling sites were more likely to use brochures and newsletters than high enrolling sites. High enrolling sites also perceived mailing study brochures to local physicians to be ineffective.

Other recruitment strategies

Additional recruitment strategies included the use of multiple referral sources, forming a recruitment committee for rigorous site selection and comprehensive recruitment

Table 1. Characteristics of selected papers and their individual parent studies.

Author of paper	Recruitment aim(s) of paper	Parent Study Design	Target Population	Recruitment period	Target of parent study	Sites (n)	Country	Length of follow up	Study visits (n)
Berk et al. (2017) ¹²	To examine methods that enabled the STEADY-PD III trial to recruit their target population	STEADY-PD III	CTIMP to assess the disease-modifying potential of isradipine	Early stage idiopathic PD patients above the age of 30 at the time of diagnosis; not currently receiving symptomatic therapy and not projected to require PD symptomatic therapy for at least 3 months from baseline visit	336 participants (with mandatory 10% target of participants from marginalized racial and ethnic groups)	18 months	USA and Canada	36 months	12 in person 4 remote (phone calls)
Di Luca et al. (2023) ¹⁴	To compare the enrollment of STEADY-PD III and SURE-PD3	As above	CTIMP to assess the disease-modifying potential of inosine	As above Early stage PD patients unlikely to require dopaminergic drug therapy other than an existing stable dose of a monoamine oxidase B inhibitor within 3 months of environment	As above 270 participants (with encouraged 10% target of participants from marginalized racial and ethnic groups)	As above Not stated	As above	As above 6 As above USA	As above 24 As above Not stated
Dobkin et al. (2020) ¹⁵	To determine digital marketing strategy cost and whether strategies were associated with increased recruitment overall and from under-represented groups	Fox Insight	An online observational study	PD patients and healthy volunteers; ≥ 18 years and English literate	No sample size specified	Ongoing since 2014	Not applicable	Worldwide	Not stated (several years)
Myers et al. (2022) ¹⁶	To compare effectiveness of five recruitment strategies of three remote decentralized observational studies	A web based, decentralized cross sectional observational study	PD patients and healthy volunteers enrolled in Fox Insight	200 participants	Not specified	Not applicable	Worldwide	Not applicable	2 remote video visits 4 remote video visits
Silva de Lima et al. (2017) ¹⁷	To compare effectiveness of recruitment strategies between a North America and Netherlands cohort	Parkinson@home	Longitudinal observational study	300 participants 420 participants	Not specified	Not applicable	Worldwide USA and Canada	several years	3 remote video visits (including baseline)
				PD patients carrying the LRRK2 G2019S variant and healthy volunteers enrolled in the 23andMe research program		Not applicable	36 months	24 months	12 smartphone assessments
				PD patients previously enrolled in the SURE-PD3 or STEADY-PD III trials		Not applicable	24 months	12 web-based surveys	
				Netherlands: Individuals ≥30 years with a self-diagnosis of PD and in possession of a smartphone;	Netherlands: 12 weeks	Not applicable	Netherlands, USA and Canada		Netherlands: 1 in-person baseline visit (Netherlands);
				North America: Individuals ≥18 years with a self-diagnosis of PD, in possession of a smartphone, participation in the Fox Insight Online Study	North America: 6 weeks				North America: remote via email
		Ls-I	CTIMP to assess the	174 participants	Not specified	46	North America	5 years	Not specified

(continued)

Author of paper	Recruitment aim(s) of paper	Parent Study	Parent Study Type and Design	Target Population	Projected enrolment period	Recruitment Target of parent study	Sites (n)	Country	Length of follow up	Study visits (n)
Tilley et al. (2012) ¹³	To increase racial/ethnic diversity of participants		disease-modifying potential of creatine	PD patients. Other inclusion criteria not detailed in paper	(with an encouraged ≥9% target of participants from diverse race and ethnicity)	(actual enrollment period was 3 years)			(unsure whether US and Canada)	

STEADY-PD: Safety, Tolerability, and Efficacy Assessment of Sareplene for Parkinson Disease; CTIMP: Clinical Trials of Investigational Medical Products; PD: Parkinson's disease; USA: United States of America; FIVE: Fox Insight Validation Effort; VALOR-PD: Virtual Assessment of LRRK2 Carriers to Optimize Research in Parkinson's disease; AT-HOME PD: Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson's Disease trials; LS-I: Long-Term Study I.

support for sites, as well as reduced protocol complexity.¹² Although this study managed to recruit to target six months ahead of schedule and reach 10% minority inclusion, these strategies were not individually assessed and so their effectiveness is unknown.

Three studies that were compared in one paper¹⁶ enhanced their recruitment strategies to include more comprehensive email or phone contact methods. However, the outcomes for each study were measured differently, with one of these studies seeing no improvement on email click rate, while another saw an increase in the consent to contact rate for database participants. The other study in this paper utilized the addition of calls made outside business hours which the authors concluded resulted in improvements in the weekly pre-screening rate.

Unsuccessful recruitment strategies included the use of community settings such as PD support groups,¹⁷ as measured by comparative recruitment with a study cohort who used different recruitment methods. The use of churches and other venues¹³ to disseminate study information was also deemed unsuccessful, as described in qualitative interviews.

Also suggested as being unsuccessful were attempts to directly engage clinicians and site staff by teleconference and training events,^{13,16} both of which were reported as being poorly attended. However, their effect on recruitment is not directly assessed and so their individual effectiveness is unknown.

Discussion

This review aimed to identify strategies that have been shown to be effective for supporting recruitment and retention of people with PD to clinical research studies. Evidence from six papers reporting on interventions to support recruitment in three CTIMPs and five observational studies was included. There was considerable heterogeneity in aim, recruitment strategies, and measurement of effectiveness, with many reporting the success of a package of recruitment methods rather than individual strategies.

Retention

The lack of studies that measured or investigated the effectiveness of retention strategies was a key finding of this review, highlighting an important knowledge gap. There is qualitative data exploring participant trial experience and the barriers and facilitators to retention,^{7,18–20} however, this knowledge has not been translated into evaluable retention strategies. Insights from similar studies may be used to devise strategies that could be formally tested within trials.

The effect of the recruitment strategy on retention was not evaluated in any of the papers. Such evaluation has been carried out in a range of other disease areas providing valuable insights.²¹ The failure of the papers included in

Table 1. Continued.

Table 2. Recruitment strategies used per study and key conclusions.

Author	Recruitment Strategies	Comparator and Outcomes Measured	Key Results
Berk et al. (2017) ¹²	STEADY-PD III • Recruitment committee • Rigorous selection and activation of sites • Recruitment toolkit • Reduced protocol complexity • Comprehensive outreach and awareness strategy • Recruitment committee and rigorous site selection	Primary Outcome (Comparator): Monthly and total number of participants enrolled (actual vs. anticipated number of participants recruited) Other outcomes measured: 1. Effectiveness of referral sources (self-reported study referral source) 2. Effectiveness of study webinars and podcasts on disease modifying therapies that highlighted the ongoing trial (number of page views to study website over time) 3. Site recruitment activity (comparison of sites that met recruitment goals to the 2013 CSDD benchmark) 4. Qualitative analysis of site responses to a recruitment activity questionnaire (enrollment categories)	Primary outcome: The study recruited to their 336 recruitment target 6 months ahead of schedule (3.9%). 1. The top four study referral sources were: site personnel (53.8%), neurologists (24%), Fox Trial Finder (10.2%), and communications from The Michael J. Fox Foundation (3.9%). Study website traffic increased after each media release, particularly webinars. Data was collected from 54/57 sites, of which 20.4% met recruitment goals (compared to 39% CSDD benchmark), 24.1% exceeded goals (compared to 13% CSDD benchmark) and 55.6% fell below their goals (compared to 37% CSDD average). Themes emerging from qualitative analysis were 1) goal setting; 2) site team communication; 3) anticipated recruitment barriers; 4) use of recruitment toolkit materials; 5) community engagement; and 6) patient tracking methods.
Di Luca et al. (2023) ¹⁴	STEADY-PD III • Translated study and recruitment materials • Recruitment toolkit • 10% minority inclusion mandated by the funder; this sponsor requirement was directly communicated to sites and research coordinators stipulating additional minority recruitment initiatives • Minority Recruitment Application for extra funding • Local initiatives with events in collaboration with lay and professional organizations • Participation in RECRUIT study	Primary Outcome (Comparator): Number of participants recruited (compared between studies) Other outcomes measured 1. Number of participants consented 2. Number of participants randomized 3. Proportion of participants consented from marginalized or ethnic backgrounds (comparison of number of minority participants consented per study) 4. Proportion of participants randomized from marginalized or ethnic backgrounds (comparison of number of minority participants randomized per study)	STEADY-PD III As above 1. 413 participants consented 2. 336 participants randomized 3. Forty-three (10.4%) minority participants consented 4. Thirty-four (10.1%) minority participants randomized
Dobkin et al. (2020) ¹⁵	SURE-PD3 • Translated study materials • Recruitment toolkit • 10% minority inclusion encouraged • Network-based recruitment initiative to use medical records to reach out directly to primary care physicians • Participant reimbursement debit card system Fox Insight • Facebook campaign for late PD • Google campaign for early PD • Facebook campaign for geotargeting those in rural areas • Broad online campaign for all people with PD	Primary Outcome (Comparator): Number of participants recruited per strategy (compared to a baseline control group defined as six weeks with no paid digital promotion) Other outcomes measured 1. Number of targeted participants recruited 2. Proportion of minority participants recruited 3. Recruitment rate (number of total and targeted participants recruited per 10 days) 4. Cost per new participant recruited	SURE-PD3 Facebook campaign for late PD Primary Outcome: 1. 585 participants consented 2. 298 participants randomized 3. Thirty-eight (6.6%) minority participants consented 4. Sixteen (5.4%) minority participants randomized
			Facebook campaign for early PD Primary Outcome: 356 participants were recruited 1. 134 (37.6%) participants had early PD compared to 38 in the control group 2. 38 non-white and Hispanic participants were recruited (10.7%) 3. 69/80 participants were recruited per 10 days (26.27 of which had early PD) 4. \$43.77 per new participant
			Facebook campaign for rural participants Primary Outcome: 362 participants were recruited 1. 65 (18.0%) participants were in rural locations compared to 4 in the control group 2. 31 non-white and Hispanic participants were recruited (8.5%) 3. 164/55 participants were recruited per 10 days (29.55 of which were in rural locations) 4. \$43.77 per new participant

(continued)

Table 2. Continued.

Author	Recruitment Strategies	Comparator and Outcomes Measured	Key Results
Myers et al. (2022) ⁶	FIVE • Email invitation to random Fox Insight participants • This was enhanced after not meeting recruitment targets to include increased email batch size, modified email language emphasizing the role of participants in advancing knowledge of PD, a reminder email and customized emails towards healthy controls	Broad paid online campaign Primary Outcome: 5919 participants were recruited 1. 4689 (79.2%) participants had PD compared to 88 in the control group 2. 430 non-white and Hispanic participants were recruited (7.3%) 3. 4553.08 participants were recruited per 10 days (3605.92 of which had PD) 4. Cost not described	
VALOR-PD		Primary Outcome (Comparator): Number of participants recruited (compared to target sample size, and between studies) Other outcomes measured 1. Percentage of participants with consent to contact who completed pre-screen, consented to participate and attended baseline visit respectively 2. Reasons for non-participation (self-reported, time-point not known) 3. Speed of recruitment (< FIVE=weekly average consent to contact rate: VALOR-PD=average email click rate of opened emails; AT-HOME PD=mean number of participants pre-screened per week) 4. Demographics of recruited participants 5. Satisfaction and future remote research participation	As above Primary Outcome: 203 participants were recruited (159 with and 44 without self-reported PD) 1. Of those who consented to contact, 70.9% completed pre-screen, 63.5% consented to study participation and 77.8% completed the baseline visit The most common reason for non-participation was being too busy (50% of 12 participants) Average consent to contact rate increased when strategy modifications were made (from 8% up to 19%) 3.9% of PD participants recruited were non-white Most participants (76.1%) reported they would be willing to participate in future clinical trials that include video visits. 62% of all participants self-reported they would be more willing to attend future remote observational trials, and 52% remote interventional trials than trials with all in-person visits
AT-HOME PD		VALOUR-PD Primary Outcome: 277 participants were recruited (60 with and 217 without self-reported PD) 1. Of those who consented to contact, 89.4% completed pre-screen, 79.2% consented to study participation and 74.9% completed the baseline visit 2. The most common reason for non-participation was being too busy (24.2% of 33 participants) 3. Average email click rate of 24% did not improve after strategy modifications were made 4. The proportion of non-white participants recruited was so small that it was not reported 5. Most participants (87.6%) reported they would be willing to participate in future clinical trials that include video visits. 65% of all participants self-reported they would be more willing to attend future remote observational trials, and 60% remote interventional trials than trials with all in-person visits	As above Primary Outcome: 226 PD participants were recruited 1. Of those who consented to contact, 68.9% completed pre-screen, 48.4% consented to study participation and 45.6% completed the baseline visit 2. The most common reason for non-participation was a lack of interest in ongoing research participation (50% of 114 participants) 3. The mean number of participants pre-screened per week increased when strategy modifications were made (from 4.7 up to 14) 4. 4.4% of participants recruited were non-white 5. 65% of all participants self-reported they would be more willing to participate in future trials with some remote assessments, and 40% with all remote assessments than trials with all in-person visits
Silva de Lima et al. (2017) ⁷	Parkinson@home North America cohort • Emails to Fox Insight participants • Facebook adverts to targeted populations • Adverts on Fox Trial Finder Netherlands cohort • Support groups • Internet communities • Physiotherapists specialized in treating PD patients	Primary Outcome (Comparator): Total number of enrolled participants and number of eligible registrants that did not complete the informed consent (compared between participant cohorts) Other outcomes measured 1. Demographics of recruited participants	Primary Outcome: In the North America cohort: 866 participants were invited and 649 were recruited (75%); In the Netherlands cohort, 347 participants were invited and 304 were recruited (88%) 1. The Netherlands cohort recruited more participants who were male, older and higher educated

(continued)

Author	Recruitment Strategies	Comparator and Outcomes Measured			
		Key Results			
Tilley et al. (2012) ³	Ls-I • Supplemental funding for a recruitment coordinator with strong connection to local diverse communities • Funding for events with community physicians to reduce concern about medical research • Website for community physicians with study info and patient FAQs • Study training for clinic specialists and recruitment coordinators • Public information brochures in English and Spanish for patients • Sample letter to mail to their PD patients regarding the trial • A business agreement meeting/Health Insurance Portability and Accountability Act (HIPAA) requirements was made available to physicians who wanted help in reviewing their charts to identify PD patients • A list of local community physicians located in areas of high diversity surrounding each study site	<p>Primary Outcome (Comparator): Total number of participants recruited from intervention sites (compared to control sites)</p> <p>Other outcomes measured</p> <ol style="list-style-type: none"> Minority recruitment (proportion of participants recruited from racial and ethnically diverse backgrounds Qualitative interviews with investigators and coordinators of high and low enrolling sites Number and type of recruitment activities collated through monthly web-based activity logs Primary reason for exclusion among those screened 	<p>Primary Outcome: 349 participants were enrolled by the 17 intervention and 257 participants were enrolled by the 15 control sites</p> <ol style="list-style-type: none"> 44 minority participants (12.6%) were recruited from the intervention sites, and 41 (16.0% from the control sites) Use of targeted recruitment in churches and other venues had limited success; Brochures and newsletter were more likely to be used by low enrollers and high enrolling sites saw these an ineffective: Low enrollers indicated minority participants refused participation due to the length of the study, medication could be purchased over the counter; economic barriers such as cost of transportation or mistrust in research; Some low enrollers considered recruiting diverse participants too costly in terms of the enroller's time and effort required to overcome barriers; High enrollers reported more community outreach and use of existing clinician relationships; High enrollers found ways to overcome participant-related barriers and commented on significant time investment into building relationships Intervention sites had more contact at local physicians' offices: Physician events were organized but poorly attended The main reasons for exclusion were unknown (40.5% white, 33.9% diverse populations of those excluded), eligibility criteria not met (24.8% white, 37.2% diverse populations of those excluded) and not interested (19.1% white, 15.7% diverse populations of those excluded) 		

STEADY-PD: Safety, Tolerability, and Efficacy Assessment of Isradipine for Parkinson Disease; CSDD: Tufts Center for the Study of Drug Development; PD: Parkinson's disease; SURIE-PD: Study of Urac Elevation in Parkinson's Disease; RECRUIT: Randomized Recruitment Intervention Trial; FIVE: Fox Insight Validation Effort; VALOR-PD: Virtual Assessment of LRRK2 Carriers to Optimize Research in Parkinson's Disease; AT-HOME PD: Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson's Disease trials; Ls-I: Long-Term Study I

this scoping review to assess the impact of their recruitment strategies on study retention could be considered a lost opportunity.

Recruitment

Several strategies were found to enhance recruitment; these included the use of research registries or trial finders, digital marketing campaigns, site recruitment support and multiple referral sources. Some recruitment strategies were suggested to have little or no effectiveness. These included the use of physical recruitment materials, the use of support groups and community settings to disseminate study information, and training and engagement events for site staff.

All but one study that employed PD specific research registries or trial finders recruited more participants compared to the study's recruitment target or study cohort that did not use this strategy. The one study that found this method ineffective¹⁶ utilized a genetics research registry and was limited to LRRK2 G2019S carriers which may explain why their recruitment target was not met. Research registries and trial finders have previously been assessed as a successful means of trial recruitment in brain diseases²² including dementia.²³ However, both trial finders and registries require significant infrastructure and support for information governance, data privacy and data storage requirements which are significant to support the large user base required to cover a breadth of representation that caters for specific recruitment needs meeting a particular study's eligibility criteria.²⁴

The use of digital marketing had a positive effect on recruitment for the two observational studies that employed this strategy. Dobkin et al.¹⁵ aimed to recruit a proportion of PD patients to their online observational study, using various online campaigns aimed at the general public. Between 17 and 37.6% of study participants recruited via targeted social media campaigns had PD, while a broad paid online campaign recruited a proportion of 79.2% PD patients. The latter recruitment strategy also included the use of emails to the Michael J Fox Foundation community, which has over 380,000 members, and a television appearance by Michael J Fox, the publicity value of which may have influenced the response rate of participants interested in the study. Berk et al.¹² demonstrated increased website traffic resulting from a heightened online presence in the form of webinars and podcasts of disease-modifying therapies that featured the parent study, which the authors consider contributed to their successful study recruitment.

Social media has been demonstrated to be an effective tool in recruiting to CTIMPs in other disease areas^{25,26} including in older adults,²⁷ although almost always deployed in conjunction with other, more traditional recruitment methods. The targeting of participants based on predefined demographic criteria is a particular advantage of social media approaches.²⁴ However, its use could introduce bias

Table 3. Summary of recruitment strategies and their effectiveness.

Recruitment strategy	Effective (reference)	Not effective (reference)	Unclear (reference)
Site recruitment support	✓(12)		
Physical recruitment materials		✓(12-14,16)	
Rigorous site selection			✓(12)
10% minority inclusion mandated by the funder ^a	✓(14)		
10% minority inclusion encouraged by the funder		✓(14)	
Minority Recruitment Application for extra funding ^a	✓(12)		
Social media advertising ^a	✓(15,17)		
Podcasts and webinars	✓(12)		
Parkinson's-specific trial finders	✓(12,17)		
Parkinson's-specific research registries	✓(16,17)		
Modification of recruitment strategies if not meeting target			✓(16)
Multiple referral sources	✓(12)		
Study specific websites to provide study information		✓(13,16)	
Training and engagement events for study staff		✓(13,16)	
Support groups to disseminate study information		✓(17)	
Community venues to disseminate study information		✓(13)	
Recruitment coordinator to connect with local diverse groups		✓(13)	

^aStrategies effective for minority participants.

Table 4. Recruitment suggestions and their potential application.

Suggestion	Potential application and benefit
Use of targeted social media campaign	Application: Planning of accurate costings during the grant writing phase Ongoing monitoring of desired participant characteristics, particularly during longer recruitment phases, to target online posts to particular study populations depending on current need Potential benefit: Reduced costs compared to using traditional recruitment methods alone; ability to recruit a more diverse participant cohort
Use of a research registry or trial finder platform	Application: Use of a large register or platform with significant infrastructural support, with the potential to aid in site selection Potential benefit: A research-ready pool of participants available for quick study screening
A tailored package of recruitment strategies specific to the target minority populations	Application: Use of community events, additional funding for study sites and a mandated minority target Potential benefit: Proportionate recruitment of minority participants, leading to more generalizable study results
Monitoring of recruitment strategies	Application: Ongoing review of site-level recruitment progress to understand further recruitment barriers and modify strategies on a case-by-case basis if needed Potential benefit: Stronger relationships with study staff and a reduced need for in-person monitoring by study sponsors

and limit representativeness of a study population: social media users tend to be younger and more computer literate; additionally some ethnic and racial groups tend to be more active on social media than others.²⁸ Nevertheless, Dobkin et al.¹⁵ found participants recruited via social media to be older, with more complicated medical histories and lower

educational attainment compared with the baseline group recruited with no paid digital promotion.

Although paid social media campaigns are costly, a recent systematic review found that social media (mainly the use of Facebook) was almost twice as cost-effective as traditional recruitment methods, and more so than other

forms of paid online advertising, although interpretability of these findings is limited by variability in patient population, target sample size, study type, location and recruitment methods leading to large variability in effect sizes.²⁹

Ongoing, systematic recruitment monitoring is essential to mitigate challenges and barriers to enrolment.³⁰ Berk et al.¹² used a recruitment committee to contact each study site monthly and amended their individual recruitment strategies, including new outreach opportunities, ways to leverage technology and the revision of recruitment materials. Although additional site support had a very positive impact on a quarter of the 57 sites in the study, deploying a such a strategy involving modifications and monthly meetings would require significant resource, particularly for longer-term trials with higher numbers of trial sites. This could be mitigated with the use of comprehensive central monitoring and adopting a risk-based approach to contacting sites who are struggling to attain their recruitment goals.

The proportion of under-served groups, including those from racial and ethnic minority backgrounds, recruited to studies remains low. Ongoing initiatives are exploring these communities' knowledge and attitudes towards PD research.³¹ Of the three papers that addressed this in their aims,^{13–15} two identified strategies which may be successful in increasing recruitment diversity. A Google advertising campaign resulted in the recruitment of 10.7% non-white and Hispanic participants to an online observational study,¹⁵ however due to the recruitment of healthy controls it is not known how many participants in this group had PD. When comparing the three CTIMPs which aimed to recruit a target proportion of racial and ethnic minorities, the study that utilized the provision of funding specific to minority recruitment, and setting of mandatory minority recruitment goals recruited a higher proportion of marginalized racial and ethnic participants¹² than those that had encouraged goals,¹⁴ or had a singular strategy of a recruitment coordinator to connect with local diverse groups.¹³ Due to the multifaceted nature of research participation barriers, recruitment strategies for minority PD patients should be both multi-layered and tailored to the individual needs of specific minority populations at the time of study design.^{32,33}

Several strategies, including the use of physical recruitment materials and interventions aimed at study recruiters were suggested to not improve recruitment. Two recent systematic reviews found recruitment interventions targeting site staff were of insufficient quality to allow conclusions to be drawn.^{2,34} Although once a core route of targeted recruitment, the ability for site staff to access potential study participants' medical histories and discuss eligibility requirements with clinicians has been impacted following the adoption of more innovative remote trial designs following the COVID19 pandemic.³⁵ Additionally, the former systematic review found the use of churches and other community venues to disseminate study information may enhance recruitment. The broader entry criteria compared

to those of PD studies, and the fact there may have been a low prevalence of PD patients attending church settings may reflect why this conclusion is not supported by the findings of this scoping review.

Another aspect to consider is the types of study identified in this review. Recruitment to an observational study is a very different proposition to recruitment to a more complex and intensive CTIMP. Only two of the three CTIMPs in this review recruited to target, with one achieving this 6 months ahead of schedule.¹² The simplified protocol, including less stringent eligibility criteria and using change in total UPDRS score in the medications' ON state as the primary outcome measure may have contributed to this more rapid recruitment, particularly as PD patients may have difficulty with OFF assessments in longer-term trials.⁷ Additionally, the country in which a study was based may have influenced the results as each has their own healthcare and research infrastructure.

Study limitations

The findings in this review are limited by the exclusion of grey literature and studies published in non-English languages. A lack of formal critical appraisal also means the quality of the papers included was not assessed. A narrow definition of the research question may have limited eligibility of studies. Finally, the presence of possible publication bias, particularly considering the limited number of studies, may have resulted in the overrepresentation of the efficacy of identified strategies.

Implications for future Parkinson's disease trials

It is not possible to draw firm conclusions from this review regarding recruitment strategies for PD trials, due to the limited scope of evidence and heterogeneity of reported strategy content and evaluation. Costs of strategies were only reported for digital marketing campaigns in a single paper and there were no data on further resources such as personnel time. These factors may affect applicability of particular strategies for individual trials. It is also not known whether any of the recruitment activities were co-created with Parkinson's patients. Involvement of the target population in all aspects of trial design is known to reduce barriers to participation, particularly for older adults,³⁶ and so their input into the development of recruitment strategies is vital. Nevertheless, several suggestions can be made in terms of recruitment interventions for PD trials and how these could be applied (Table 4).

Conclusion

This review has highlighted different strategies that may increase not only the rate, but the diversity of recruitment to PD clinical research studies. Further studies evaluating retention strategies in PD studies are needed.

Acknowledgments

We would like to thank Chris Johns, Information Specialist from the University of Plymouth who assisted with search strategy development, and all additional PPIE working group members for their input.

ORCID iDs

Petty Rebecca  <https://orcid.org/0000-0001-7734-6905>
 Bartolomeu-Pires Sandra  <https://orcid.org/0000-0003-3711-9040>
 Boey Timothy  <https://orcid.org/0000-0003-1601-4821>
 Gonzalez-Robles Cristina  <https://orcid.org/0000-0001-6809-0127>
 Allgar Victoria  <https://orcid.org/0000-0002-5228-2623>
 Carroll Camille B  <https://orcid.org/0000-0001-7472-953X>
 Zeissler Marie-Louise  <https://orcid.org/0000-0002-6232-4284>

Statements and declarations

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was conducted as part of the Edmond J Safra Accelerating Clinical Trials in Parkinson's Disease (EJS ACT-PD) Initiative, which is funded by the Edmond J Safra Foundation. This work was also supported by funding from the MRC-NIHR Trials Methodology Research Partnership (TMRP) Doctoral Training Partnership (DTP)."

Declaration of conflicting interests

CBC and TF are Editorial Board members of this journal, but were not involved in the peer-review process nor had any access to information regarding its peer review.

Data availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during this study

Supplemental material

Supplemental material for this article is available online.

References

1. Parkinson's UK. The incidence and prevalence of Parkinson's in the UK: Results from the Clinical Practice Research Datalink Summary report, <https://www.parkinsons.org.uk/sites/default/files/2018-01/CS2960%20Incidence%20and%20prevalence%20report%20branding%20summary%20report.pdf> (2018, accessed 15 February 2024).
2. Gardner HR, Fraser C, MacLennan G, et al. A protocol for a systematic review of non-randomised evaluations of strategies to improve participant recruitment to randomised controlled trials. *Syst Rev* 2016; 5: 131.
3. National Institutes of Health (U.S.). *Outreach notebook for the inclusion, recruitment and retention of women and minority subjects in clinical research: Principal Investigators' notebook*. USA: National Institutes of Health, Office of Research on Women's Health, Office of Extramural Research, NIH Outreach Notebook Committee, NIH Tracking and Inclusion Committee, 2002.
4. Hewitt CE, Kumaravel B, Dumville JC, et al. Assessing the impact of attrition in randomized controlled trials. *J Clin Epidemiol* 2010; 63: 1264–1270.
5. U.S. Food and Drug Administration. Enhancing the diversity of clinical trial populations—eligibility criteria, enrollment practices, and trial designs guidance for industry, <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial> (2020, accessed 16 February, 2024).
6. McGhee DJM, Ritchie CW, Zajicek JP, et al. A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease. *BMC Neurol* 2016; 16: 92.
7. Kehagia AA, North TK, Grose J, et al. Enhancing trial delivery in Parkinson's disease: qualitative insights from PD STAT. *J Parkinsons Dis* 2022; 12: 1591–1604.
8. Vaswani PA, Tropea TF and Dahodwala N. Overcoming barriers to Parkinson disease trial participation: increasing diversity and novel designs for recruitment and retention. *Neurotherapeutics* 2020; 17: 1724–1735.
9. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med* 2018; 169: 467–473.
10. Amir-Behghadami M and Janati A. Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. *Emerg Med J* 2020; 37: 387.
11. McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer review of electronic search strategies: 2015 guideline statement. *J Clin Epidemiol* 2016; 75: 40–46.
12. Berk S, Greco BL, Biglan K, et al. Increasing efficiency of recruitment in early Parkinson's disease trials: a case study examination of the STEADY-PD III trial. *J Parkinsons Dis* 2017; 7: 685–693.
13. Tilley BC, Mainous AG 3rd, Elm JJ, et al. A randomized recruitment intervention trial in Parkinson's disease to increase participant diversity: early stopping for lack of efficacy. *Clin Trials* 2012; 9: 188–197.
14. Di Luca DG, Macklin EA, Hodgeman K, et al. Enrollment of participants from marginalized racial and ethnic groups. *Neurology* 2023; 13: e200113.
15. Dobkin RD, Amondikar N, Kopil C, et al. Innovative recruitment strategies to increase diversity of participation in Parkinson's disease research: the fox insight cohort experience. *J Parkinsons Dis* 2020; 10: 665–675.
16. Myers TL, Augustine EF, Baloga E, et al. Recruitment for remote decentralized studies in Parkinson's disease. *J Parkinsons Dis* 2022; 12: 371–380.
17. Silva de Lima AL, Hahn T, Evers LJW, et al. Feasibility of large-scale deployment of multiple wearable sensors in Parkinson's disease. *PLoS One* 2017; 12: e0189161.

18. Rossi A, Torres-Panchame R, Marcus AR, et al. What makes a group fitness program for people with Parkinson's disease endure? A mixed-methods study of multiple stakeholders. *Complement Ther Med* 2018; 41: 320–327.
19. Rowsell A, Ashburn A, Fitton C, et al. Participant expectations and experiences of a tailored physiotherapy intervention for people with Parkinson's and a history of falls. *Disabil Rehabil* 2022; 44: 727–735.
20. O'Brien M, Dodd KJ and Bilney B. A qualitative analysis of a progressive resistance exercise programme for people with Parkinson's disease. *Disabil Rehabil* 2008; 30: 1350–1357.
21. Gillies K, Kearney A, Keenan C, et al. Strategies to improve retention in randomised trials. *Cochrane Database Syst Rev* 2021; 3: MR000032.
22. Zwan MD, Van Der Flier WM, Cleutjens S, et al. Dutch brain research registry for study participant recruitment: design and first results. *Alzheimers Dement (N Y)* 2021; 7: e12132.
23. Kotting P, Smith A, O'Hare MB, et al. A national open-access research registry to improve recruitment to clinical studies. *Alzheimers Dement (N Y)* 2021; 7: e12221.
24. Ng CE, Bowman S, Ling J, et al. The future of clinical trials—is it virtual? *Br Med Bull* 2023; 148: 42–57.
25. Ortner VK, Zibert JR, Budnik O, et al. Accelerating patient recruitment using social media: early adopter experience from a good clinical practice-monitored randomized controlled phase I/IIa clinical trial on actinic keratosis. *Contemp Clin Trials Commun* 2024; 37: 101245.
26. Raviotta JM, Nowalk MP, Lin CJ, et al. Using Facebook™ to recruit college-age men for a human papillomavirus vaccine trial. *Am J Mens Health* 2016; 10: 110–119.
27. Cowie JM and Gurney ME. The use of Facebook advertising to recruit healthy elderly people for a clinical trial: baseline metrics. *JMIR Res Protoc* 2018; 7: e20.
28. Oudat Q and Bakas T. Merits and pitfalls of social media as a platform for recruitment of study participants. *J Med Internet Res* 2023; 25: e47705.
29. Tsaltskan V, Sanchez Baez R and Firestein GS. Cost-effectiveness of social media advertising as a recruitment tool: a systematic review and meta-analysis. *J Clin Transl Sci* 2023; 7: e180.
30. McDaniel JC, Rausch JA and McGowan DR. Monitoring and modifying recruitment and retention strategies for an ongoing randomised clinical trial with venous leg ulcer patients: overcoming barriers to participation. *Int Wound J* 2023; 20: 1042–1052.
31. Sanchez AV, Ison JM, Hemley H, et al. Designing the fostering inclusivity in research engagement for underrepresented populations in Parkinson's disease study. *Contemp Clin Trials* 2022; 115: 106713.
32. Picillo M, Kou N, Barone P, et al. Recruitment strategies and patient selection in clinical trials for Parkinson's disease: going viral and keeping science and ethics at the highest standards. *Parkinsonism Relat Disord* 2015; 21: 1041–1048.
33. Adrissi J and Fleisher J. Moving the dial toward equity in Parkinson's disease clinical research: a review of current literature and future directions in diversifying PD clinical trial participation. *Curr Neurol Neurosci Rep* 2022; 22: 475–483.
34. Treweek S, Pitkethly M, Cook J, et al. Strategies to improve recruitment to randomised trials. *Cochrane Database Syst Rev* 2018; 2: MR000013.
35. The Association of the British Pharmaceutical Industry. Clinical research in the UK: an opportunity for growth, https://www.abpi.org.uk/media/g0anpn5o/abpi_clinical-trials-report-2021.pdf (2021, accessed 21 May, 2024).
36. The Lancet Healthy L. Increasing patient and public involvement in clinical research. *Lancet Healthy Longev* 2024; 5: e83.